JP2008508319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008508319A5 JP2008508319A5 JP2007523879A JP2007523879A JP2008508319A5 JP 2008508319 A5 JP2008508319 A5 JP 2008508319A5 JP 2007523879 A JP2007523879 A JP 2007523879A JP 2007523879 A JP2007523879 A JP 2007523879A JP 2008508319 A5 JP2008508319 A5 JP 2008508319A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- independently selected
- substituted
- hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 3
- 230000029812 viral genome replication Effects 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- IWUCXVSUMQZMFG-RGDLXGNYSA-N 1-[(2s,3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 IWUCXVSUMQZMFG-RGDLXGNYSA-N 0.000 claims 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 229960000329 ribavirin Drugs 0.000 claims 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 101710088194 Dehydrogenase Proteins 0.000 claims 1
- HAEJPQIATWHALX-KQYNXXCUSA-N ITP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HAEJPQIATWHALX-KQYNXXCUSA-N 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- 108010078233 Thymalfasin Proteins 0.000 claims 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229960001388 interferon-beta Drugs 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 claims 1
- 229950006081 taribavirin Drugs 0.000 claims 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims 1
- 229960004231 thymalfasin Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/903,215 US20050182252A1 (en) | 2004-02-13 | 2004-07-29 | Novel 2'-C-methyl nucleoside derivatives |
| US65252705P | 2005-02-11 | 2005-02-11 | |
| PCT/US2005/027235 WO2006033709A2 (en) | 2004-07-29 | 2005-07-29 | Novel nucleoside derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008508319A JP2008508319A (ja) | 2008-03-21 |
| JP2008508319A5 true JP2008508319A5 (enExample) | 2008-09-11 |
Family
ID=36090428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007523879A Withdrawn JP2008508319A (ja) | 2004-07-29 | 2005-07-29 | 新規ヌクレオシド誘導体 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1781101A2 (enExample) |
| JP (1) | JP2008508319A (enExample) |
| WO (1) | WO2006033709A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101479290A (zh) * | 2006-06-27 | 2009-07-08 | 比奥维特罗姆上市公司 | 新的2′,3′-亚甲基缩醛腺苷前药用作腺苷受体激动剂的前药 |
| US20080187928A1 (en) | 2006-12-29 | 2008-08-07 | The Salk Institute For Biological Studies | Methods for enhancing exercise performance |
| TW200936146A (en) * | 2007-11-29 | 2009-09-01 | Metabasis Therapeutics Inc | Antiviral nucleoside compounds |
| EP2421879B1 (en) * | 2009-04-22 | 2013-09-04 | Institute Of Organic Chemistry And Biochemistry As CR, V.V.I. | Novel 7-deazapurine nucleosides for therapeutic uses |
| JP6562908B2 (ja) | 2013-10-11 | 2019-08-21 | ヤンセン バイオファーマ インク. | 置換ヌクレオシド、置換ヌクレオチドおよびその類似体 |
| EP3623364A1 (en) | 2014-02-13 | 2020-03-18 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
| AU2015280248B2 (en) * | 2014-06-24 | 2021-04-08 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| NZ727582A (en) * | 2014-06-24 | 2018-06-29 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| CN106687118A (zh) | 2014-07-02 | 2017-05-17 | 配体药物公司 | 前药化合物及其用途 |
| WO2018031818A2 (en) * | 2016-08-12 | 2018-02-15 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| CN109956986B (zh) * | 2017-12-22 | 2021-04-27 | 浙江柏拉阿图医药科技有限公司 | 肝递送吉西他滨前体药物核苷环磷酸酯化合物及应用 |
| CN114644666A (zh) * | 2020-12-18 | 2022-06-21 | 上海特化医药科技有限公司 | 5’-核苷前药的制备方法及中间体 |
| US20240166680A1 (en) * | 2021-04-15 | 2024-05-23 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Nucleoside analog and use thereof |
| CN113816836B (zh) * | 2021-09-29 | 2024-05-03 | 山东睿鹰制药集团有限公司 | 一种(s)-1-(4-氯苯基)-1,3-丙二醇的酶法生产方法 |
| WO2023111683A1 (en) * | 2021-12-16 | 2023-06-22 | Ascletis Bioscience Co., Ltd. | N4-hydroxycytidine derivatives and use thereof as antiviral agent |
| US11541071B1 (en) * | 2021-12-16 | 2023-01-03 | Ascletis BioScience Co., Ltd | Nucleoside derivatives and methods of use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5374626A (en) * | 1989-09-22 | 1994-12-20 | Farmitalia Carlo Erba | 5'-alkylphosphonylnucleosides as antivirals |
| EP0767657A4 (en) * | 1994-06-22 | 1999-01-20 | Nexstar Pharmaceuticals Inc | NOVEL PROCESS FOR THE PRODUCTION OF KNOWN AND NEW NUCLEOSIDES, MODIFIED IN THE 2 'POSITION BY INTRAMOLECULAR NUCLEOPHILIC DISPLACEMENT |
-
2005
- 2005-07-29 EP EP05807817A patent/EP1781101A2/en not_active Withdrawn
- 2005-07-29 JP JP2007523879A patent/JP2008508319A/ja not_active Withdrawn
- 2005-07-29 WO PCT/US2005/027235 patent/WO2006033709A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008508319A5 (enExample) | ||
| JP2007522237A5 (enExample) | ||
| GEP20094751B (en) | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same | |
| WO2004002422A3 (en) | 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | |
| WO2004014313A3 (en) | Combination pharmaceutical agents as inhibitors of hcv replication | |
| JP2008530096A5 (enExample) | ||
| JP2010510234A5 (enExample) | ||
| JP2016503800A5 (enExample) | ||
| JP2012504126A5 (enExample) | ||
| JP2012504632A5 (enExample) | ||
| HK1200022A1 (en) | Combination treatment (e.g. with abt-072 or abt-333) of daas for use in treating hcv | |
| WO2006000922A3 (en) | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae | |
| JP2011520906A5 (enExample) | ||
| JP2004517047A5 (enExample) | ||
| TW200500373A (en) | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | |
| JP2013521279A5 (enExample) | ||
| WO2005123087A3 (en) | C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase | |
| CA2577745A1 (en) | Hcv inhibiting bi-cyclic pyrimidines | |
| HRP20160410T1 (hr) | Inhibitori hepatitis c virusa | |
| SI1719773T1 (sl) | Kondenzirane heterotetraciklične spojine in njihova uporaba kot inhibitorji polimeraze HCV | |
| RU2008152171A (ru) | Новые ингибиторы вирусной репликации гепатита с | |
| JP2012512169A5 (enExample) | ||
| WO2001077091A3 (en) | Ns5b hcv polymerase inhibitors | |
| WO2007076034A3 (en) | Anti-viral compounds | |
| WO2007081517A8 (en) | Anti-viral compounds |